Interstitial lung disease

1. Diagnosis and differential diagnosis (i.e. Hepato-pulmonary syndrome, telomeropathies, sarcoidosis aspects, Hermansky-Pudlak syndrome, Niemann-Pick disease and Gaucher disease)
2. CTD features
3. Haematological diseases
4. Occupational disease
5. Pulmo-renal syndromes
6. Genetic testing in ILDs

1. Bronchoalveolar lavage/bronchial biopsy and forceps transbronchial lung biopsy
2. Indication and contraindication for cryobiopsy technique including complications of transbronchial cryobiopsy

1. Indications and contraindications for EBUS and EUS
2. Theory of sample processing and rapid on-site evaluation

1. Indications
2. Contraindications
3. Complications

1. Limitations and indications of chest X-rays
2. Basic interpretation of chest radiographs
3. Radiological correlates of chest organs and bony chest structures
4. Describing radiological findings of a chest radiograph
5. Recognition of abnormal results and formulation of a diagnosis

1. Early detection
2. Ultrasound appearance

1. Technique of multi-slice thickness CT (high resolution CT (HRCT) for ILD diagnostics
2. Patterns and differential diagnosis
3. Computer-based quantification options and limitations

1. Steroids and immunomodulators used to treat ILD
2. Antifibrotic drugs for pulmonary fibrosis

Indications, limitations and role of respiratory physiotherapy in ILD

Indications, limitations and role of pulmonary rehabilitation in ILD

1. Principles of palliative care
2. Early integration of palliative care, multidisciplinary care and communication

1. Prescription according to current statements and guidelines
2. Criteria for long-term oxygen therapy (LTOT) in patients with ILD
3. Ambulatory oxygen

1. General aspects of preventative measures (vaccination, sports)
2. Dietary measures
3. Exercise
4. Influenza vaccination
5. Pneumococcal vaccination
6. SarsCoV2 vaccination
7. Specific preventative management
8. Smoking cessation

1. Limitations of assisted ventilation in advanced cases
2. High-flow oxygen
3. Extracorporeal membrane oxygenation
4. High-frequency oscillatory ventilation
5. CPAP in OSA/ILD overlap

1. Indications and contraindications for lung transplantation
2. Indications for early referral
3. Indications for lung transplantation in patients with systemic diseases
4. Challenges around pharmacotherapy in ILD and transplant

1. Differential diagnosis of respiratory emergencies
2. Acute exacerbation of fibrosing ILDs

1. Early referral to a specialist ILD centre
2. Multidisciplinary diagnosis for ILD

Diffuse parenchymal lung disorders manifesting with acute lung injury

1. Clinical aspects
2. Diagnostic aspects
3. Treatment of IPF
4. Acute exacerbation of IPF in patients already known to be affected by IPF
5. Identification of patients with IPF and significant emphysema
   1. CT scan features
   2. Pulmonary function tests focusing on the discrepancy between volume preservation and significant reduction of carbon monoxide diffusing capacity (DLCO)

1. General aspects of lung cancer
2. Lung cancer in the context of ILD
3. Immunotherapy and ILD

1. ILD appearing with acute respiratory failure
2. Differential diagnosis
3. Diagnostic approaches
4. Treatment

1. Clinical aspects
2. Diagnostic modality
3. Treatment of different subtypes, including life-threatening organ involvement (heart, central nervous system, hypercalcemia and others)

1. Idiopathic interstitial pneumonias including cryptogenic organising pneumonia of unknown aetiology/bronchiolitis obliterans organising pneumonia
2. Smoking-related idiopathic interstitial pneumonia and Combined Pulmonary Fibrosis and Emphysema (CPFE)
3. Pleuro-parenchymal fibroelastosis
4. Non-specific interstitial pneumonia
5. Progressive fibrosing ILD
   1. Diseases with PF-ILD
   2. Treatment of PF-ILD

1. Of known causes
2. Of unknown causes
3. High-resolution computed tomography (HRCT) scan features
4. Pulmonary function tests
5. Diagnostic work-out
6. Treatment

1. CTD-ILD: a clinical overview
2. Treatments of CTD-ILD

1. General clinical overview
2. Pathogenesis
3. Treatment

1. General clinical overview
2. Pathogenesis
3. Treatment

1. General clinical overview
2. Pathogenesis
3. Treatment

1. General clinical aspects
2. Pathogenesis
3. Treatment

1. General aspects of drug-induced disease
2. Pathogenesis
3. Treatment

Radiation-induced disease

1. Clinical aspects
2. Pathogenesis
3. Treatment

1. Pathophysiology of pulmonary hypertension
2. Pharmacological treatment of pulmonary hypertension according to the underlying disease
3. Diagnosis of pulmonary hypertension
4. Translating national and international management guidelines to an individual patient
5. Appropriate decisions for referral and transfer to specialised referral centres

1. Definition of the main entities
2. Granulomatosis with polyangiitis (GPA)
3. Eosinophilic granulomatosis with polyangiitis (EGPA)
4. Microscopic polyangiitis

Pleural disease

1. Aspects of primary immunodeficiency syndromes
2. Differential diagnosis

Secondary immunodeficiency syndromes/immunosuppression

1. General aspects of cardiac disease
2. Differentiation between cardiac and pulmonary diseases as a cause of acute respiratory failure
3. Differential diagnosis of the cardiac causes of acute respiratory failure
4. Invasive cardiovascular monitoring (e.g. Swan-Ganz catheterisation)
5. Cardiovascular effect of positive pressure ventilation

General aspects of lung damage related to gastrointestinal and liver diseases and renal failure in the context of ILD

General aspects of haematological disease

1. General aspects of Birt-Hogg-Dubé syndrome
2. Clinical, radiological and histopathological features
3. Genetic background and biology
4. Detection of tumours during follow-up
5. Treatment modality, including participation in clinical trials, and genetic counselling

1. Clinical evaluation of patient
2. Differential diagnosis
3. Treatment, intervention, mitigation
4. Disability, vocational considerations, Workers’ Compensation considerations
5. Public health approach

1. General aspects of acute inhalation injuries and their possible sequelae
2. Identification of smoke inhalation and burns as causes of respiratory failure
3. Assessment of the degree of severity of pulmonary involvement
4. Optimal treatment of inhalation injury, including systemic effects

General aspects of ILD caused by dusts of biologic origin

General aspects of asbestos-related conditions other than bronchopulmonary cancer (but including mesothelioma)

General aspects of epidemiological and statistical methods